References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
- González-Martin A, Mira E, Mañes S. CCR5 as a potential target in cancer therapy: inhibition or stimulation?. Anticancer Agents Med Chem 2012; 12:1045 - 57; http://dx.doi.org/10.2174/187152012803529637; PMID: 22583417
- Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521 - 30; http://dx.doi.org/10.1016/S0092-8674(00)80438-9; PMID: 9390561
- Kim KW, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G, et al. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 2011; 118:e156 - 67; http://dx.doi.org/10.1182/blood-2011-04-348946; PMID: 21951685
- Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadière C, Prévot S, et al. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One 2011; 6:e21546; http://dx.doi.org/10.1371/journal.pone.0021546; PMID: 21750716
- Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007; 14:1226 - 34; http://dx.doi.org/10.1038/sj.gt.3302959; PMID: 17597794
- Tardáguila M, Mira E, García-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res 2013; 73:4461 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-12-3828; PMID: 23720051
- Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, et al. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res 2000; 60:3722 - 6; PMID: 10919640
- Mira E, Lacalle RA, González MA, Gómez-Moutón C, Abad JL, Bernad A, et al. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2001; 2:151 - 6; http://dx.doi.org/10.1093/embo-reports/kve027; PMID: 11258708
- Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402:884 - 8; PMID: 10622253